How to bridge the gap between academia and industry
Shared interests, mutual gain, flexibility and trust are key to building win–win partnerships in drug development.
Connecting and engaging those who care about cancer
International oncology experts reunited as one oncology community to share the latest advances in the field at the ESMO annual meeting starting next week
A Virtual Train to ESMO travelling through 15 countries
With the “departure” of the virtual ESMO train in August, the ESMO Young Oncologists Committee (YOC) and the ESMO Climate Change Task Force are creating new opportunities for networking and sharing knowledge, while raising awareness on how climate change hits on cancer care
BrighTNess trial: no benefit from the addition of veliparib to neoadjuvant chemotherapy in TNBC
Long-term outcomes of the phase III study confirm that only the addition of carboplatin to paclitaxel impacts on pathological complete response and event-free survival
The right to be forgotten reduces financial toxicity in cancer survivors
Reduced access to insurance, bank loans and mortgages makes financial constraints continue long after cancer has been treated
More than one in six cancer patients experience long-term effects of COVID-19
OnCOVID study reveals that respiratory symptoms, fatigue and cognitive/psychological dysfunction persist after acute Sars-CoV-2 infection, with an impact on survival and oncological outcomes after recovery
Virtual Plenary Debate, a new session not-to-be missed
Presented at the ESMO Virtual Plenaries this year, four key studies in oncology will animate the debate
CheckMate 743 reinforces the role of immunotherapy in first-line mesothelioma
Nearly 1 in 4 patients with pleural malignancy continue to benefit from nivolumab plus ipilimumab at 3 years
From empiric testing to rational design: two decades of progress in phase I trials
Ensuring equitable access to innovative treatments is now the major challenge in oncology, says Prof. Alex Adjei